{
  "document_id": "HOUSE_OVERSIGHT_024100",
  "filename": "IMAGES-007-HOUSE_OVERSIGHT_024100.txt",
  "text": "XIII. APPENDICES\n\nAppendix 1\n\nListing of Investments by Fund\n\nNew Leaf Ventures II, L.P.\n$ amounts in millions, as of March 31, 2014\nPlease refer to Endnotes 1,J,K,L,M and N in this Appendix.\n\nGross\nMultiple Gross\nVintage Realized Unrealized Total (Realized Multiple\nCompany Year Total Cost Value Value Value Portion) (Total) Gross IRR\n\nRealized or Partially Realized Investments\n\nAcadia Phamaceuticals, Inc. Therapeutics 7.7 19.4 - 19.4 2.51 2.51 581.9%\nAmbit Biosciences, Inc. Therapeutics 2013 10.4 11.1 - 11.1 1.06 1.06 13.1%\nArray Biopharma Inc. Therapeutics 2012 9.0 20.3 - 20.3 2.25 2.25 74.0%\nAudax Health Solutions, Inc. Convergence 2011 88: 125 1.6 14.1 - 3.68 105.6%\nChimerix, Inc. Therapeutics 2011 20.6 27.0 44.9 71.9 3.07 3.50 57.7%\nEpizyme, Inc. Therapeutics 2013 3.4 6.8 - 6.8 2.03 2.03 1583.0%\nGlumetrics, Inc. Diagnostics & Infrastructure 2008 10.7 - - - - - NM\nIntercept Pharmaceuticals, Inc. Therapeutics 2012 10.5 34.1 - 34.1 3.24 3.24 323.6%\nKalidex Pharmaceuticals, Inc. Therapeutics 2011 2.4 02 - 0.2 0.07 0.07 -91.6%\nMEI Pharma, Inc. Therapeutics 2012 9.0 10.2 35.8 46.0 2.94 5.12 423.2%\nPresidio Pharmaceuticals, Inc. Therapeutics 2009 11.0 - - - - - NM\nSynageva BioPharma Therapeutics 2009 10.4 75.7 - 75.7 7.30 7.30 103.3%\nWorldheart, Inc. Healthcare Devices 2008 17.0 1.8 - 1.8 0.11 0.11 NM\nTotal Realized or Partially Realized Investments $ 125.9 $ 219.2 ยง$ 82.3 $ 301.5 2.01 2.39 40.6%\nAdvanced Cell Diagnostics, Inc. Diagnostics & Infrastructure 2012 9.0 - 9.0 9.0 - 1.00 -0.4%\nAfferent Pharmaceuticals, Inc. Therapeutics 2009 11.2 - 11.2 11.2 - 1.00 0.0%\nAltura Medical, Inc. Healthcare Devices 2010 10.7 - 8.3 8.3 - 0.77 -12.3%\nAwareP oint Corporation Convergence 2011 12.8 - 14.1 14.1 - 1.10 5.7%\nCalchan Holdings LTD Therapeutics 2011 De - - - - - NM\nCardioKinetix, Inc. Healthcare Devices 2011 12.0 - 12.0 12.0 - 1.00 0.0%\nConvergence Pharmaceuticals, Ltd Therapeutics 2010 7A - 7.6 7.6 - 1.03 1.0%\nDurata Therapeutics, Inc. Therapeutics 2009 25.0 - 40.8 40.8 - 1.63 21.2%\niRhythm Technologies, Inc. Convergence 2011 11.1 - 11.6 11.6 - 1.04 1.6%\nKaros Pharmaceuticals, Inc. Therapeutics 2010 7.6 0.1 75 7.6 - 1.00 0.0%\nKarus Therapeutics Ltd Therapeutics 2012 5.8 - 5.8 5.8 - 1.00 0.0%\nKaryopharm Therapeutics, Inc. Therapeutics 2013 1.0 - 4.2 4,2 - 417 1638.7%\nKitcheck, Inc. Convergence 2013 3.7 - 3.7 3.7 - 1.00 0.0%\nNeuronetics, Inc. Healthcare Devices 2009 20.3 - 21.9 21.9 - 1.08 2.0%\nNY Digital Health, LLC Convergence 2012 0.4 - 0.4 0.4 - 1.00 0.1%\nOxford Immunotec Diagnostics & Infrastructure 2009 11.3 - 27.1 27.1 - 2.41 28.3%\nPrincipia BioPharma, Inc. Therapeutics 2011 9.7 - 9.7 9.7 - 1.00 0.0%\nSpiracur, Inc Healthcare Devices 2009 12.0 - 8.5 8.5 - 0.70 -8.4%\nTigerText, Inc. Convergence 2012 4.6 0.0 5.6 5.7 - 1.25 22.6%\nTreato Pharma Convergence 2013 3.0 - 3.0 3.0 - 1.00 0.0%\nTruveris, Inc. Convergence 2012 6.5 - 6.5 6.5 - 1.00 0.0%\nVersartis, Inc. Therapeutics 2011 21.2 - 93.6 93.6 - 4.41 129.4%\nPublic Investments Therapeutics 2011 20.6 13.1 29.5 42.6 - 2.07 42.5%\nTotal Unrealized Investments $ 232.1 ยง$ 13.2 ยง 341.4 ยง$ 354.6 - 1.53 20.4%\n\n89 CONTROL NUMBER 257 - CONFIDENTIAL\n\nHOUSE_OVERSIGHT_024100",
  "metadata": {
    "original_filename": "IMAGES-007-HOUSE_OVERSIGHT_024100.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 3159,
    "word_count": 526,
    "line_count": 59,
    "import_date": "2025-11-19T21:47:48.094985",
    "prefix": "IMAGES-007"
  }
}